Skip to main content
. 2023 Apr 6;15(8):573–581. doi: 10.2217/imt-2022-0311

Table 4. . Cost–effectiveness results from the Medicare scenario analysis.

  Atezolizumab BSC Incremental atezolizumab vs BSC ICER
Total cost ($) 276,479 229,097 47,382 48,512/QALY
QALYs 6.302 5.325 0.977

BSC: Best supportive care; ICER: Incremental cost–effectiveness ratio; QALY: Quality-adjusted life-year.